A new era in the treatment of melanoma: from biology to clinical practice

作者：Marquez Rodas Ivan^*; Martin Algarra Salvador; Aviles Izquierdo Jose Antonio; Custodio Cabello Sara; Martin Miguel

来源：Clinical and Translational Oncology, 2011, 13(11): 787-792.

DOI：10.1007/s12094-011-0734-6

• Melanoma
• Apoptosis
• Immune system
• Vemurafenib
• Ipilimumab

Melanoma is the deadliest cutaneous malignancy and its incidence continues to grow. Until 2011, the treatment options for metastatic melanoma were scarce and without any overall survival benefi t. The emergence of new targeted therapies for BRAF mutant melanoma (vemurafenib) and immunotherapy (ipilimumab) has changed the standard of care for this disease. The objective of the present review is to summarise the biological background of the new therapeutic approaches in melanoma, focusing on apoptosis resistance, immune modulation and angiogenesis, and the direct translation into clinical practice.

• 出版日期2011-11